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Peroxisome Proliferator-Activated Receptor-a Is a
Functional Target of p63 in Adult Human
Keratinocytes
Silvia Pozzi1, Michael Boergesen2, Satrajit Sinha3, Susanne Mandrup2 and Roberto Mantovani1
p63 is a master switch in the complex network of signaling pathways controlling the establishment and
maintenance of stratified epithelia. We provide evidence that peroxisome proliferator-activated receptor-a
(PPARa), a ligand-activated nuclear receptor that participates in the skin wound healing process, is a target of
p63 in human keratinocytes. Silencing of p63 by RNA interference and transient transfections showed that p63
represses PPARa through a functional region of promoter B. Chromatin immunoprecipitation analyses indicate
that p63 is bound to this region, in the absence of a recognizable p63-binding motif, suggesting that it acts
through interactions with other transcription factors (TFs). Distinct PPARa transcripts are differentially regulated
by p63, indicating a bimodal action in promoter and/or transcription start specification. PPARa repression is
consistent with lack of expression in the interfollicular epidermis under physiological conditions. Furthermore,
we show that PPARa is a negative regulator of DNp63a levels and that it also binds to a functional region of the
DNp63 promoter that lacks PPRE motifs. Therefore, the reciprocal regulation is exerted either through binding
to non-consensus sites or through interactions with other DNA-bound TFs. In conclusion, our data establish a
link between two TFs intimately involved in the maintenance of skin homeostatic conditions.
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INTRODUCTION
p63, a transcription factor (TF) member of the p53 family,
plays a unique role in skin development as lack of this protein
in mice causes perinatal lethality due to several abnormal-
ities, including the absence of stratified epithelia and their
appendages (Mills et al., 1999; Yang et al., 1999). p63 exerts
its indispensable biological role through a number of protein
variants displaying opposite functions, all possessing a DNA-
binding domain and an oligomerization domain (Yang et al.,
1998; Ghioni et al., 2002; Westfall et al., 2003). p63 diversity
is achieved through differential promoter usage, yielding
proteins either possessing (TA) or lacking (DN) a transactiva-
tion domain. Moreover, alternative splicing of TAp63 and
DNp63 proteins at the C terminus gives rise to a-, b-, and
g-isoforms (Yang et al., 1998), all of which possess different, if
not divergent, transactivating properties.
Compelling genetic analyses support the hypothesis that
DNp63 is essential for the proliferative potential of cells in
stratified epithelia (Parsa et al., 1999; Yang et al., 1999;
Senoo et al., 2007). The presence of a pool of keratinocytes
capable of self-renewal is paramount for skin homeostasis,
including the ability to intervene when a dermal/epidermal
injury occurs. As a counterproof, transgenic mice in which
epidermal-specific DNp63a knockdown was induced after
birth were characterized by severe skin fragility and
displayed an impaired ability to heal skin wounds (Koster
et al., 2007).
Studies conducted on both rodent and human models
indicate that peroxisome proliferator-activated receptors
(PPARs) are key players in the skin wound healing process.
Three distinct PPARs—a, b/d, and g, exhibiting distinct tissue
distribution and different ligand specificities—have been
described (Kliewer et al., 1994; Mukherjee et al., 1994;
Auboeuf et al., 1997). In mouse and human keratinocytes,
PPARb/d is the most abundant isoform in adults, whereas g is
not expressed (Braissant and Wahli, 1998; Michalik et al.,
2001; Westergaard et al., 2001). PPARa, expressed mainly in
tissues with a high rate of b-oxidation such as liver, brown fat,
and skeletal muscle (Gonzalez, 1997 and references within),
is detectable in the hair follicles (Braissant and Wahli, 1998;
Michalik et al., 2001) but barely traceable in the inter-
follicular epidermis (Westergaard et al., 2001). However,
upregulation of PPARa and PPARb/d expression can be
observed in the interfollicular epidermis upon proliferation
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stimuli or hair plucking and during wound healing (Michalik
et al., 2001).
Although targeted disruption of PPARa in mouse models
had no significant consequences on the skin phenotype (Lee
et al., 1995; Komuves et al., 2000), the onset of the skin
wound healing process was transiently delayed both in mice
lacking PPARa (Michalik et al., 2001) and in those
engineered to express a dominant negative PPARa in the
epidermal compartment (Michalik et al., 2005). Conversely,
PPARa constitutive activation targeted to the mouse epider-
mis and other stratified epithelia led to dramatic phenotypic
changes in the skin and other ectodermally derived epithelia,
namely the mammary gland and tongue, with pups dying
within 2 days after birth (Yang et al., 2006a).
Thus, p63 and PPARa are key regulators of skin home-
ostasis in mammals. The finding of p63 at the injured site
during the healing process (Noszczyk and Majewski, 2001;
Bamberger et al., 2005; Kurokawa et al., 2006), as well as
expanding knowledge of p63 transcriptional targets (Yang
et al., 2006b; Birkaya et al., 2007; Vigano` and Mantovani,
2007), led us to investigate whether there is a direct interplay
between p63 and PPARa.
RESULTS
p63 is a negative regulator of PPARa expression in adult human
keratinocytes
Results from Affymetrix expression profiling of HaCaT cells
that were untreated or transiently silenced for p63 (Testoni
et al., 2006a) prompted us to investigate the correlation
between p63 and PPARa, as inactivation of p63 led to an
increase in PPARa expression. We sought to confirm
this in HaCaT and first-passage primary human keratinocytes
(KCs). RNA interference (RNAi) of p63, targeting the DNA-
binding domain common to TA/DNp63a, b, and g, led to an
overall increase in PPARa splicing isoforms compared with
cells transfected with a green fluorescent protein control
RNAi; the mRNA was checked by semiquantitative and
quantitative real-time RT–PCR (Figure 1a), and the protein
levels were examined by Western blot (Figure 1b). Ectopic
expression of different human PPAR subtypes in COS
cells probed with the same anti-PPARa antibody ensured
that the signal detected was specific for the a subtype (Figure
1c). The larger than expected size of PPARa, observed in
HepG2 and COS cells upon PPARa overexpression, is
consistent with the latter being phosphorylated in vivo
(Gervois et al., 1999).
Differential promoter usage and alternative splicing at the
N-terminus have been described for PPARa (Figure 1d;
Pineda-Torra et al., 2002; Chew et al., 2003, 2007), resulting
in several splicing isoforms sharing a common open reading
frame (Vohl et al., 2000). We explored whether distinct
PPARa isoforms contributed equally to the observed
overall increase: the most prominent feature was an increase
in PPARa-4 on p63 removal, which was paralleled by a
decline in PPARa-6, in both HaCaT and KCs (Figure 1a,
bottom left). Note that the two splicing isoforms are generated
by promoter B but do not share a common transcription
start site (TSS) (Chew et al., 2003 and Figure 1d). PPARa-5
and -2 levels, driven by promoters A and C, respectively,
were not significantly affected in KCs. Finally, confocal
analysis of human skin from healthy donors stained with anti-
p63 and anti-PPARa antibodies showed the absence of
PPARa expression in the intact interfollicular epidermis
(data not shown), consistent with previous reports
(Westergaard et al., 2001). In conclusion, in keeping with
our profiling experiments, PPARa expression is influenced by
p63 levels.
PPARa is a direct target of p63
Modulation of PPARa expression could be either a secondary
event mediated by other TFs or a primary one directly exerted
by p63 bound to regulatory elements on the PPARa locus. To
address this point, we performed in silico analysis of the
PPARa gene searching for p63-, p53-, and PPARa-like
consensus sites. We scanned the human PPARa gene by
combining sequence-specific binding requirements for each
TF ( Juge-Aubry et al., 1997; Ortt and Sinha, 2006; Perez
et al., 2007) and bioinformatic tools—ConSite and rVista—
and identified several putative sequences (Figure 2a).
Chromatin immunoprecipitation (ChIP) in HaCat with two
different antibodies directed against p63 revealed in vivo
binding to several regions upstream of TSS (Figure 2b, left
panels). Furthermore, ChIPs with antibodies against PPARa
and its heterodimeric partner RXR indicate that the two TFs
are present on some, but not all, regions positive for p63,
notably promoters A and B (Figure 2b, right panels). Several
genomic regions were negative for all antibodies. The FDXR
promoter region, used as a positive control for p63 binding
(Vigano` et al., 2006), was indeed positive for p63, but not for
PPARa or RXR, whereas a previously identified PPARa locus,
corresponding to amplicon 2 (Pineda-Torra et al., 2002), was
positive for both PPARa and RXR. Finally, we performed the
same assays in primary keratinocytes and indeed found
similar results, notably on amplicons in promoter A and
promoter B (Figure 2c). Overall, these data indicate that p63
occupies several binding sites in vivo in keratinocytes and
suggest that PPARa/RXR might be involved in an auto-
regulatory process, as previously hypothesized (Pineda-Torra
et al., 2002).
p63 represses PPARa promoter B
Next, we tested the transcriptional activity of p63 on reporter
plasmids containing PPARa promoter A 1664/þ81 or B
1147/þ 34. PPARa promoter A 1664/þ 81 contains the
TSS for both PPARa isoforms 5 and 3 (Figure 3a).
Transient transfections were carried out in U2OS, which
lack p63, and in HaCaT, which express almost exclusively
DNp63a (Yang et al., 1999). Expression of TAp63a, -b, or -g
or DNp63a or -g in U2OS cells significantly (Po0.5 and
Po0.02) downregulated promoter A activity, whereas
expression of DNp63b led to a modest increase (Po0.05)
(Figure 3b). Note that the increases in expression observed
with low doses of TAp63a and TAp63g were not statistically
significant. Under similar conditions, promoter A activity
was unchanged in HaCaT cells (Figure 3c). In keeping with
this result, knockdown of p63 by RNAi had negligible
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effects on the transcription of promoter A in HaCaT cells
(Figure 3d).
PPARa promoter B 1147/þ 34, containing the TSS of
PPARa-4, but not that for PPARa-6 (Figure 3e), in U2OS cells
was repressed by ectopic p63 in a dose-dependent manner,
with a stronger effect (Po0.02) in the presence of TAp63b
and -g and DNp63a and -g (Figure 3f). In HaCaT cells, only
DNp63a significantly (Po0.02) repressed promoter B, with
DNp63b and -g showing modest (Po0.05) activation (Figure
3g). Indeed, functional inactivation of endogenous DNp63a
in the same cells enhanced (Po0.02) the activity of promoter
B (Figure 3h). Amplicon 4 of promoter B was positive for
binding in vivo (Figure 2) and included in the 1147/þ34
construct. To ascertain whether this p63 location was
implicated in promoter B regulation, we generated 50 deletion
constructs comprising 500/þ 34 or lacking 200/þ34
such region (Figure 3i, left). Transient transfection in HaCaT
cells showed a significant (Po0.02) decrease of the promoter
B 500/þ34 construct with increasing amounts of DNp63a
(Figure 3i, right). In contrast, the activity of the 200/þ34
construct was not changed by p63 overexpression.
Altogether, these data strongly suggest that the in vivo
binding of p63 to amplicon 4 mediates PPARa promoter B
downregulation.
To further validate the role of p63 on PPARa promoter B
activity, we overexpressed different isoforms of p63 in HaCaT
and KCs (Figure 4a). To this aim, we monitored endogenous
PPARa-4 mRNA, as scored by semiquantitative RT–PCR; in
both HaCaT and KCs the drop was substantial (Figure 4a). In
addition, ectopic expression of DNp63a and -g led to a
decrease in PPARa-6 mRNA levels, also generated by
promoter B, in HaCaT cells but not in KCs (Figure 4a, left
and right, respectively). Total PPARa mRNA levels were
repressed by all ectopically expressed p63 isoforms in
HaCaT cells as well as in KCs (Figure 4b). However, only
ectopic expression of DNp63a led to a significant repression
of PPARa protein levels (Figure 4c). Taken together, these
data provide evidence that p63, and DNp63a in particular, is
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Figure 1. p63 is a negative regulator of PPARa expression in adult human keratinocytes. (a) RT–PCR (left) and qRT–PCR (right) analyses of PPARa expression in
HaCaT cells and KCs transiently (96 hours) transfected with 3 mg of either a plasmid encoding a short hairpin targeting GFP as a control (GFP RNAi) or one
targeting all p63 isoforms (p63 RNAi). cDNAs were normalized versus GAPDH levels. Results are representative of at least three independent experiments.
(b) Western blotting analysis of PPARa protein expression in HaCaT and KCs as described in (a). Protein loading was normalized versus vinculin. (c) Western
blotting proving the specificity of the anti-PPARa antibody by ectopic expression of human PPAR subtypes (1.5 mg each) in COS cells. (d) PPARa gene structure
(adapted from Chew et al., 2003), splicing isoforms, and protein. PA, PB, PC, and PD represent the four characterized promoters.
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a repressor of PPARa transcription, specifically targeting a
functional element between 469 and 255 of promoter B
that drives PPARa-4 expression in adult human
keratinocytes.
PPARa is a negative regulator of p63
Recently, a TF regulated by p63, C/EBP delta, was shown to
affect the expression levels of p63 isoforms (Borrelli et al.,
2007). We then explored the possibility that there is also a
reciprocal interplay between p63 and PPARa; HaCaT cells
were infected with lentivirus expressing short hairpin RNA
against PPARa and LacZ (negative control). Stable
knockdown of PPARa by three different lentiviral constructs
(#1, #2, #3) led to an increase in DNp63 mRNA, detected by
quantitative real-time RT–PCR (Figure 5a, left); the levels of
the DNp63a protein were also positively regulated in western
blot analysis (Figure 5a, right). To determine whether PPARa
regulation of the DNp63a promoter is direct, we scanned for
the presence of PPARa-binding sites in DNp63 regulatory
regions (Figure 5b, left): the proximal promoter (Romano
et al., 2006) and the evolutionarily conserved enhancer
located in the fifth intron (Antonini et al., 2006). ChIP analysis
indeed detected PPARa and RXR binding to the DNp63
promoter and 1 kb downstream of the TSS in HaCaT cells
(Figure 5b, right panels). p63 was bound to its own
promoter and downstream regions, as previously assessed
(Antonini et al., 2006; Borrelli et al., 2007; Romano et al.,
2006, and Figure 5b, left panels). Upstream regions (from
1.5 to 3 kb) were negative for p63 and PPARa binding
(data not shown).
To understand whether PPARa binding to DNp63 promo-
ter regions was involved in transcriptional downregulation,
we used three DNp63 constructs differing at the 50 end (Figure
5c, left), with partial overlap of the two amplicons (A and B)
bound in vivo by PPARa. On transient transfection in a p63-
negative background—COS cells—the basal activity of the
two longer constructs, 1584/þ69 and 736/þ69, was
similar, whereas the shorter core promoter construct 164/
þ 69 showed a twofold drop. However, the activity of the
longer DNp63 constructs, but not of the core promoter, was
significantly (Po0.05 and Po0.02) downregulated by
increasing amounts of ectopic PPARa, either alone or in
the presence of RXRa (Figure 5c, right). In essence, these
data support the hypothesis that PPARa behaves as a
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Figure 2. PPARa is a p63 target. (a) Schematic representation of human PPARa genomic region. Transcription start sites (TSS) for each promoter and in silico
identified consensus for TFs are shown. Double arrows represent the positions of amplicons generated by PCR after chromatin IP (ChIP) assay, identified by
numbers on the bottom. Region 2 comprises a consensus for hepatocyte nuclear factor 4 (HNF4), which is a positive control for PPARa binding (Pineda-Torra
et al., 2002). (b) Amplification of genomic regions, numbered as in (a), after ChIP, showing the in vivo binding of p63 and PPARa, as well as its heterodimeric
partner RXR, to PPARa. The amplified FDXR promoter region is a positive control for p63 binding in human KCs (Vigano` et al., 2006). Results are representative
of three to five independent ChIP assays. (c) ChIPs performed on KCs.
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transcriptional regulator of DNp63a expression in adult
human keratinocytes.
DISCUSSION
In this paper, we show that DNp63a and PPARa, two TFs that
are paramount for skin homeostasis in mammals, impinge on
each other’s expression in human keratinocytes. Silencing
of p63 resulted in a dramatic increase in PPARa expression.
This effect is promoter- and isoform-specific, and it is
mediated, at least in part, by the direct binding of p63 to
the regulatory elements in the PPARa promoter B region.
Similarly, knockdown of PPARa induces DNp63 mRNA and
protein expression.
Besides being essential for skin stratification and correct
appendage formation during embryonic development (Mills
et al., 1999; Yang et al., 1999), p63 is the gatekeeper for the
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Figure 3. p63 represses PPARa promoter B. (a) Schematic diagram of PPARa promoter A-luciferase construct 1664/þ 81, used in transient transfections. The
position of amplicons 2 and 3 generated after ChIP are indicated by double arrows. (b) U2OS cells, devoid of endogenous p63, were exposed to increasing
amounts (70–210 ng) of p63 expression constructs for 24 hours. (c) HaCaT cells, expressing high levels of DNp63a, were transfected with increasing amounts
(50–100 ng) of Tap63a or DNp63a, b, and g encoding plasmids or (d) transiently knocked down (72 hours) for GFP (GFP RNAi) as a control or p63 (p63 RNAi)
before transfection with 1.2 mg of the reporter construct for an additional 24 hours. (e) Schematic diagram of PPARa promoter B-luciferase construct 1147/þ 34
used in transient transfections as described in (b). The position of amplicon 4 generated after ChIP is indicated by double arrows. (f, g, and h) Transient
transfection of U2OS and HaCaT cells as described in (b, c and d) using the PPARa promoter B-luciferase 1147/þ 34 construct. (i) Left: schematic diagram of 50
deletions of PPARa promoter B, 500/þ 34 and 200/þ 34, used in transient transfection in HaCaT cells as described above. The position of amplicon 4
generated after ChIP is indicated by double arrows. All results, shown as mean±SD of three independent experiments, each conducted in triplicate, are
expressed as fold variation over the promoter-only construct, arbitrarily set as 1. Values were normalized by co-transfection with the 200 ng CMV-bGal
construct. Statistical significance was calculated using the Student’s t-test (*Po0.5; **Po0.01).
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balance between self-renewal and differentiation in multi-
layered epithelia. In particular, the role in skin homeostasis of
the major isoform expressed in keratinocytes—DNp63a—is
well established. Regulation of PPARa expression is stun-
ningly complex, as it involves at least four promoters and a
plethora of splicing isoforms. A clear indication of the
complexity of regulation of the PPARa locus by p63 stems
from the ChIP analysis, which pinpoints binding to six
different locations, mapping on all four promoters. Although
we obtained clear evidence for a p63 function only on
promoter B, other units could be regulated under conditions
different from the ones used here in growing keratinocytes.
This complexity is further reflected by the bimodal activity of
DNp63a on the various isoforms present in human keratino-
cytes; the mutual exclusivity of PPARa-6 and -4 suggests that
p63 might be involved in the choice of the TSS and/or in
subsequent splicing events. This is not unprecedented, as we
have recently shown that another p63 target, the antiapopto-
tic FLIP, is more controlled at the level of splicing isoform
selection than overall mRNA production (Borrelli et al.,
2009). The precise mechanisms of these activities are
currently unknown. In particular, it is unclear whether this
is the result of selection of particular PolII-associated
complexes loaded differentially onto the promoters or of
activation of distinct splicing factors by p63. We note that
p63 ChIP-on-chip analysis retrieved statistically enriched GO
terms of genes controlling mRNA metabolism (Vigano` et al.,
2006 and Pozzi et al., 2009).
DNp63a-negative regulation of PPARa in human kerati-
nocytes is consistent with PPARa being scarcely detectable in
the lower layers of adult interfollicular epidermis under
physiological conditions (Westergaard et al., 2001). This is
not always the case, as prolonged exposure to PPARa
activators (natural and synthetic fatty acid derivatives) is able
to induce differentiation, improve epidermal barrier function,
and counteract hyperproliferation in several mouse models of
skin disorders displaying features of exacerbated inflamma-
tion (Michalik and Wahli, 2007; Schmuth et al., 2008). In
general, PPARa is a key negative modulator of the
inflammatory response in the skin compartment. Further-
more, PPARa mRNA levels are reduced in psoriatic lesions
and atopic dermatitis in humans (Westergaard et al., 2003;
Michalik and Wahli, 2007; Staumont-Salle et al., 2008),
whereas p63 levels tend to be maintained high and possibly
higher in psoriasis (Shen et al., 2005; Gu et al., 2006).
The negative regulation of DNp63 by PPARa, as evidenced
by the increase in mRNA and protein levels upon RNAi
inactivation of PPARa and ChIP assays, suggests a complex
feedback loop between the two TFs. One physiological
response in which the two TFs play a role is the
reepithelialization of a wound, which initially involves the
migration of basal keratinocytes from the injury edges and
hair follicles and their proliferation, stratification, and
differentiation. Transient expression of PPARa is induced
after an injury, and PPARa-deficient mice are characterized
by a transient delay in the healing process, overlapping with
the temporal window of the inflammatory response. As for
the p63 behavior in this process, two mouse models indicate
a relevant role: (i) skin lesions of transgenic mice with
constitutive expression of DNp63a targeted to the epidermal
basal layer are not healed (Sommer et al., 2006) and (ii)
conditional p63 knockout mice are severely impaired in skin
wound healing (Koster et al., 2007). The kinetics of DNp63a
expression are consistent with a role in the process, as it is
transiently downregulated in mouse and human skin at early
stages of wound healing and rebounds for several days after
complete wound closure (Noszczyk and Majewski, 2001;
Bamberger et al., 2005; Kurokawa et al., 2006). At present, it
is unclear which mechanisms are responsible for this
repression in vivo, but the identification here of PPARa
makes it an excellent candidate for mediating this process on
the DNp63 promoter during wound healing.
Interestingly, ChIP analysis convincingly shows interac-
tions of p63 on PPARa promoter B and of PPARa on the
DNp63 promoter, yet bioinformatic analysis fails to show the
presence of canonical binding sites for the two TFs; thus, the
reciprocal regulation is apparently exerted either through
binding to non-canonical sequences or through association
with undefined TFs binding to the two regions. This
mechanism of regulation is unprecedented for PPARs, but
not for p63; indeed, the latter has been shown to negatively
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blotting (top panels) proving the efficiency of ectopic p63 expression in
HaCaT (left) and KCs (right) and semiquantitative RT–PCRs (bottom panels)
showing PPARa-4 and -6 expression driven by promoter B. Results are
representative of two independent experiments. Amplification of GAPDH
ensured cDNA normalization. (b) qRT–PCR of global PPARa mRNA
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(c) Western blotting showing PPARa protein levels in HaCaT after p63 ectopic
expression. Protein loading was normalized versus laminin.
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regulate promoters specifically active in the G2/M phase of
the cell cycle through CCAAT boxes and by direct association
with the CCAAT-binding TF NF-Y (Testoni and Mantovani,
2006b). In fact, NF-Y has been shown to be the intended
target for other TFs. Interestingly, the DNp63 promoter does
contain two key CCAAT boxes, but a deletion mutant
containing only this region lost the capacity to be regulated
by PPARa, implying that NF-Y is not the intended target.
Additional work must be performed to identify the molecular
details of this regulation on the two promoters. In general,
work originally done on nuclear receptors in the early 1990s
showed that regulation—positive and negative—of a TF on a
particular gene can be exerted not through binding to a
consensus site, but through association with another TF
(Gaub et al., 1990; Shemshedini et al., 1991); this concept
has since been extended for several TFs and further reinforced
by dozens of ChIP-on-chip studies, whereby a large propor-
tion of TF locations lack any visible recognition motif. In the
most extreme case, E2F1, only a small minority o20% of
promoter locations contain a recognizable motif (Bieda et al.,
2006).
PPARa mediates adaptation to intermittent nutritional
deprivation by stimulating the transcription of genes critical
for fatty acid oxidation (Reddy, 2001). Fatty acid synthase
converts dietary carbohydrates into saturated fatty acid
(Semenkovich, 1997) and is a transcriptional target of p63
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in human keratinocytes (D’Erchia et al., 2006). Finally, other
p63 targets emerging from ChIP-on-chip experiments are
CITED2 (Vigano` et al., 2006), a well-known PPARa
co-regulator (Tien et al., 2004), and PPARb/d (Pozzi et al.,
2009), which is paramount for skin wound healing (Michalik
and Wahli, 2007 and references therein). It is therefore
conceivable that p63 and PPARa cooperate in the physiolo-
gical response to nutrient and oxygen depletion following an
epidermal wound. In general, TF genes are among the
preferred targets of p63 (Pozzi et al., 2009). Intuitively, a
network of reciprocal regulatory interactions could be
established to drive and control the different features of a
dynamic tissue undergoing continuous, controlled growth
and terminal differentiation. Our current hypothesis is that
p63 makes key connections with, in particular, regulators of
specific functions that would constitute ‘‘hubs’’ with further
fine-regulatory missions. While adding a new hit to the
rapidly increasing list of p63 targets, we trace a direct
connection between p63, the skin repair process, and the
inflammatory phase, an essential ‘‘hub’’ in tissue integrity and
protection against external stresses, of which PPARa is an
important regulator. Further work is required to identify the
network of co-regulated targets during the process.
MATERIALS AND METHODS
Cell culture, transfection, and reporter assay
First-passage primary human keratinocytes derived from healthy
individuals were grown on a feeder layer of lethally irradiated
human fibroblasts as previously described (Vigano` et al., 2006).
HaCaT, U2OS, and COS cells were grown in DMEM supplemented
with 10% fetal calf serum. All transfections were carried out using
Lipofectamine 2000 (Invitrogen, Milan, Italy), following the manu-
facturer’s instructions. Transient transfections for reporter assay were
carried out three times in triplicate, and CMV-bGal vector was co-
transfected as an internal control for transfection efficiency. Plasmid
DNAs encoding a hairpin targeting green fluorescent protein (a kind
gift of S. Oliviero, Siena, Italy) were used as a negative control along
with that targeting the DNA-binding domain common to all p63
isoforms (Sigma, Milan, Italy). PPARa promoter A1664/þ 81 and B
1147/þ 34 reporter constructs were generous gifts from B. Staels
(Lille, France) and T.S. Tengku-Muhammad (Penang, Malaysia),
respectively. PPARa promoter B 50 deletions were generated by
amplification from the original construct 1147/þ 34 and cloned
into pGL3-basic vector (Promega, Milan, Italy) using restriction sites
for XhoI and HindIII introduced by PCR.
Lentiviral vector construction, virus production, and infection
The software program Psicoligomaker was used to select 19-mer
short hairpin RNA sequences and design sense and antisense oligos.
Sequences were BLASTed to confirm target specificity. The annealed
and phosphorylated oligos were cloned into the pSicoR puromycin
lentiviral vector (Ventura et al. 2004) using the HpaI and XhoI
restriction sites. Short hairpin RNA target sequences were as follows:
shPPARa no. 1: 50-GACTCAAGCTGGTGTATGA-30; shPPARa no. 2:
50-GAAGAGTTCCTGCAAGAAA-30; shPPARa no. 3: 50-GAATACCA
GTATTTAGGAA-30; and shLacZ: 50-GAAGGCCAGACGCGAATTA-30.
Lentiviral particles were produced by co-transfecting 293T cells with
pSicoR puromycin (10 mg) and the lentiviral packaging vectors
pMDL/RRE, pRSV-Rev, and pMD2G-VSVG (5mg each) using
metafectene (Biontex Laboratories, GmbH, Planegg, Germany).
The medium was harvested after 48 and 72 hours, pooled, and
passed through a 0.45 mm Millex-HV filter (Millipore, Copenhagen,
Denmark) before concentration by ultracentrifugation at 26,000 rpm
for 2 hours at 41C and resuspension in pure DMEM. HaCaT cells
were infected with lentivirus for 24 hours in the presence of
8mgml1 Polybrene and subsequently placed under puromycin
selection (1mgml1) for 10 days before harvest of RNA and proteins.
RT–PCR and western blotting
Total RNA was isolated using Trizol (Invitrogen) and retrotranscribed
with the SuperScript First-Strand Synthesis System (Invitrogen).
Sequences of primer pairs are available upon request. cDNAs were
normalized versus glyceraldehyde-3-phosphate dehydrogenase and/
or TATA binding protein levels. For semiquantitative RT–PCRs,
several amplifications were carried out to ensure that cDNA
amplification was in the linear range. Whole-cell extracts were
lysed in RIPA buffer. Twenty to 40mg of lysates were separated on
10% SDS–PAGE, transferred onto a nitrocellulose membrane
(Protran, Whatman, Maidstone, UK), and probed using the following
antibodies: anti-p63 (clone 4A4, Santa Cruz, Santa Cruz, CA),
anti-PPARa (Santa Cruz, CA), anti-vinculin (clone VIN-11-5, Sigma),
anti-TFIIB (Santa Cruz), and anti-laminin (Santa Cruz).
ChiP assay
ChIP analysis was carried out essentially as previously described
(Testoni et al., 2006a). In brief, 2.5 106 cell equivalents of
chromatin were immunoprecipitated with 5mg of the following
antibodies: anti-p63 (clone 4A4, Sigma; Beretta et al., 2005), anti-
PPARa and anti-RXR (Santa Cruz), and anti-flag (clone M1, Sigma) as
a negative control. The location of potential p53-, p63-, and PPARa-
binding sites was performed by in silico analysis (Transfac and
rVista; cutoff settings: 85–90%) applying single TF-specific criteria
(Juge-Aubry et al., 1997; Ortt and Sinha, 2006; Perez et al., 2007).
When KCs were used, equivalent amounts of crosslinked proteins/
DNA from three different individuals were pooled together.
Sequences of primer pairs are available upon request.
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